恩瑞格上市了吗？价格多少？

It is an iron chelator product developed by the Swiss pharmaceutical company Novartis and is used to treat iron accumulation. So, is Enriga on the market? How much does it cost?

Enrig’s listing price: Enrig’s domestic price: The price of a box is about 2,000$. For an ordinary person weighing 60kg, the cost of taking Enrige for a month is more than 24,000$. It is difficult for ordinary families to accept this price and cannot afford it! 

Fortunately, there are also foreign versions for everyone to choose from. Novartis from Switzerland imported Enrig from India. The specification is 400mg*30 tablets/box, and the price is about $700.   

The specification of Enriga produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the fluctuation of exchange rate, the price will be different. Please consult the medical companion tour for the specific price!  

Enrig was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. 

In December 2012, Enrig was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. 

On January 23, 2013, the FDA approved the new indication of Enriga for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) aged 10 years and above.  

In 2010, Enrig was approved for marketing in China and is used to treat chronic iron overload caused by frequent blood transfusions (monthly administration of concentrated red blood cells ≥ 7 mL/kg) in patients with β-thalassemia older than 6 years old; for children under 6 years old and iron overload caused by other transfusion-dependent diseases; it is currently on the market in more than 80 countries.

It is the first oral iron-removing agent approved by the US FDA that can be used routinely. Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, can significantly reduce the iron load on the heart and liver, and is easily accepted by patients. At the same time, it can also be used to treat secondary hemochromatosis, porphyria cutaneous tarda and other diseases.